Lasa Supergenerics Ltd

NSE
LASA •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Lasa Supergenerics Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
89.47% Gain from 52W Low
21.1
TTM PE Ratio
Negative PE TTM
-7.6
Price to Book Ratio
Low in industry
1.4
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is less than 1
0.1
RSI
RSI is mid-range
53.2
MFI
MFI is mid-range
67.2

Lasa Supergenerics Ltd shareholding Pattern

Promoter
53.6%
Public
46.3%

Lasa Supergenerics Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
31.60
10Day EMA
31.50
12Day EMA
31.50
20Day EMA
31.70
26Day EMA
31.70
50Day EMA
31.20
100Day EMA
29.80
200Day EMA
29.00
Delivery & Volume
Resistance & Support
32.52
Pivot
Resistance
First Resistance
33.33
Second Resistance
34.27
Third Resistance
35.08
Support
First Support
31.58
Second support
30.77
Third Support
29.83
Relative Strength Index
53.18
Money Flow Index
67.22
MACD
-0.19
MACD Signal
-0.20
Average True Range
1.72
Average Directional Index
16.06
Rate of Change (21)
-1.67
Rate of Change (125)
21.35

Lasa Supergenerics Ltd Company background

Founded in: 2016
Managing director: Omkar P Herlekar
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chainfrom discoverytodelivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad Chiplun, in the Konkan region of Maharashtra. It specialises in catalyst chemistry and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain, the Company is fully backward integrated for its key moleculesfrom discovery research up to fullscale bulk production. The Companys marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future.The Company announced the launching of 2 new block buster products with alltime strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit with a total capacity of 20 MT. It has got huge demand all over the globe as it is manufactured and have strong entry barriers. Likewise, this product fits in product selection criteria, through which the Company is confident of grabbing significant market share.Due to floods and fire in the company units, the launch of another block buster product was deferred and commercialization of Oxyclozanide prolonged for some time to accommodate existing products in the company. The company received WHO Certificate of Good Manufacturing Practices from the Food and Drug Administration authorities for its manufacturing facility situated at Khed, Ratnagiri.The Company has alliances with leading Indian and global animal health care conglomerates and uses Good Manufacturing Practice (GMP) and worldclass technologies in its operations. The Company is managed by a consortium of technocrats, including its Chairman and Managing Director Mr. Omkar P. Herlekar who are impelled by passion and propelled by niche innovation. The leadership team, which is guided by these values, is well positioned to lead into the future.The Company is determined to achieve of becoming a leading force in the niche animal health care solutions. The objective on which it was founded have always inspired sustainable growth through innovation and shall continue to do so. Today, the Company is the leading manufacturer player in veterinary APIs in India, with a wellestablished brand known for its highquality products amongst various customers.
Read More

Lasa Supergenerics Ltd FAQs

Lasa Supergenerics Ltd shares are currently priced at 32.4 on NSE and 32.46 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Lasa Supergenerics Ltd [LASA] share was 30.64. The Lasa Supergenerics Ltd [LASA] share hit a 1-year low of Rs. 17.1 and a 1-year high of Rs. 41.2.

The market cap of Lasa Supergenerics Ltd is Rs. 162.33 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of Lasa Supergenerics Ltd is 0 as of 2/22/2024 12:00:00 AM.

The PB ratios of Lasa Supergenerics Ltd is 1.43 as of 2/22/2024 12:00:00 AM

You can easily buy Lasa Supergenerics Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage